久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Onyx
Onyx
Onyx Onyx

美國Onyx Pharmaceuticals, Inc.
2009 Onyx將以8.51億美元收購抗癌藥開發商Proteolix

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. Our approved product, Nexavar? (sorafenib) tablets, is a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis. Nexavar is approved in more than 80 countries for the treatment of patients with unresectable liver cancer and in more than 90 countries for the treatment of patients with advanced kidney cancer.

As part of a broad clinical development program, Nexavar is also being evaluated in multiple Phase 3 and Phase 2 trials as a single agent or combination treatment in a wide range of cancers, including lung cancer, thyroid cancer, breast cancer, colorectal cancer, ovarian cancer, and as an adjuvant therapy for liver cancer and kidney cancer. Nexavar is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Beyond Nexavar, Onyx is pursuing a proteasome inhibition development program. The proteasome has been validated as an important clinical target in cancer, and Onyx is developing next-generation proteasome inhibitors with a high degree of selectivity, with the goal of increasing therapeutic efficacy and reducing side effects.

The lead product candidate in this program is carfilzomib, a selective, next-generation compound that is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of patients with multiple myeloma and solid tumors. Among these studies, enrollment has been completed in a Phase 2b monotherapy trial evaluating carfilzomib in patients with relapsed and refractory multiple myeloma, the pivotal trial that could support a new drug application (NDA) filing by the end of 2010 and potential accelerated approval in 2011.

In addition to carfilzomib, the proteasome inhibitor development program includes ONX 0912 (formerly PR-047), an oral proteasome inhibitor that is expected to enter Phase 1 testing in hematologic and solid tumors in 2010, and ONX 0914 (formerly PR-957), an immunoproteasome inhibitor with activity in preclinical models of autoimmune disorders.

Onyx has also established a development pipeline of anticancer compounds at various stages of clinical testing. Onyx is developing ONX 0801, a targeted alpha-folate inhibitor that recently entered into Phase 1 testing. Onyx also has options to license the rights to two Janus Kinase 2 (JAK2) inhibitors: ONX 0803, in Phase 1 studies to treat primary myelofibrosis and lymphoid malignancies, and ONX 0805, currently in preclinical development. PD 332991, an oral, small molecule cyclin-dependent kinase 4 (CDK4) inhibitor, resulted from a collaboration with Warner-Lambert Company, now Pfizer. Pfizer is responsible for all product development activities and costs. In exchange, Onyx will receive milestone payments and a single-digit royalty on any worldwide sales of the product.

Onyx common stock is traded on the Nasdaq Global Market under the symbol ONXX.

 

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 免费亚洲网站 | 成人特黄午夜性a一级毛片 成人国产一区二区三区精品 | 亚洲国产综合专区在线电影 | 国产在线高清不卡免费播放 | 亚洲精品国产精品精 | 日韩不卡一区二区三区 | 欧美日韩精品 | 亚洲欧美另类第一页 | 成人日韩 | 亚洲精品乱码久久久久久 | 精品国产不卡一区二区三区 | a级毛片在线播放 | 欧美亚洲免费 | 黑人一区二区三区中文字幕 | 日韩不卡一区 | 国产一区二区三区免费在线视频 | 成人亚洲国产综合精品91 | 91麻精品国产91久久久久 | wwwxxx欧美 | 国产精品网站在线进入 | 久久精品视频观看 | 在线观看视频一区 | 亚洲色图欧美一区 | 久久艹精品 | 手机国产精品一区二区 | 黄色在线观看免费 | 国产午夜高清一区二区不卡 | 国产精品高清视亚洲一区二区 | 国产伦精品一区二区三区视频小说 | 国产在线观看精品一区二区三区91 | 啪啪网址大全 | 91精品国产色综合久久不卡蜜 | 欧美伊人久久 | 青草视频在线观看免费 | 最新国产区 | 在线日韩亚洲 | 亚洲欧美中文日韩综合 | 欧洲高清一区二区三区试看 | 日韩有码第一页 | 香蕉久久ac一区二区三区 | 欧美国产日韩在线观看 |